Efficacy of prolotherapy in temporomandibular joint disorders with hypertonic dextrose and Polydeoxyribonucleotide (PDRN)

Background: This study evaluated the clinical efficacy of prolotherapy using hypertonic dextrose and polydeoxyribonucleotide (PDRN) in patients with temporomandibular joint disorders (TMDs) who did not respond to conventional treatments. Methods: A retrospective chart review of 66 patients diagnosed with TMD was conducted. Patients underwent prolotherapy between March and December 2024 and were classified into soft-tissue-related and bone-related TMD groups. Treatment involved injections of hypertonic dextrose or PDRN targeting anatomical structures within the temporomandibular joint (TMJ). Pain and function were assessed using the visual analog scale (VAS) and maximum mouth opening (MMO). Additional parameters, including joint sounds and jaw displacement (S deviation or L deflection), were analyzed. Outcomes were measured at baseline, after each prolotherapy session, and during the final follow-up. Statistical analyses included paired t-tests, McNemar’s tests, Analysis of Variance (ANOVA), and regression modeling. Results: Prolotherapy was administered an average of 2.3 times per patient. The baseline VAS score decreased from 4.34± 2.12 to 1.00 ± 1.58 (p < 0.001), and MMO improved from 31.0 ± 8.7 mm to 40.8 ± 4.55 mm (p < 0.001). Joint sounds, jaw displacement, and deflection also showed significant reductions. Comparative analysis of prolotherapy agents revealed no statistically significant differences between the PDRN and dextrose groups, although both demonstrated significant improvements in MMO and VAS scores. Among patients with baseline joint sounds, 23 individuals experienced complete resolution of sounds, along with significant reductions in jaw displacement (69.6% to 13.0%, p < 0.001) and deflection (52.2% to 8.7%, p < 0.001). Conclusions: Prolotherapy is an effective intervention for improving pain and jaw function in TMD patients. Both hypertonic dextrose and PDRN demonstrated significant clinical improvements on TMD prolotherapy.

Temporomandibular joint disorder; Prolotherapy; Hypertonic dextrose; Polydeoxyribonucleotide (PDRN); Pain management

[1] Wilkie G, Al-Ani Z. Temporomandibular joint anatomy, function and clinical relevance. British Dental Journal. 2022; 233: 539–546.

[2] Mortazavi N, Tabatabaei AH, Mohammadi M, Rajabi A. Is bruxism associated with temporomandibular joint disorders? A systematic review and meta-analysis. Evidence-Based Dentistry. 2023; 24: 144.

[3] Yilmaz O, Candirli C, Balaban E, Demirkol M. Evaluation of success criteria for temporomandibular joint arthrocentesis. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 2019; 45: 299.

[4] Hakala RV. Prolotherapy (proliferation therapy) in the treatment of TMD. CRANIO®. 2005; 23: 283–288.

[5] Lee W. Prolotherapy of the temporomandibular joint is denoted as a new health technology in Korea. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 2023; 49: 59–60.

[6] Ryu K, Ko D, Lim G, Kim E, Lee SH. Ultrasound-guided prolotherapy with polydeoxyribonucleotide for painful rotator cuff tendinopathy. Pain Research and Management. 2018; 2018: 8286190.

[7] Jeong W, Yang CE, Roh TS, Kim JH, Lee JH, Lee WJ. Scar prevention and enhanced wound healing induced by polydeoxyribonucleotide in a rat incisional wound-healing model. International Journal of Molecular Sciences. 2017; 18: 1698.

[8] Bitto A, Galeano M, Squadrito F, Minutoli L, Polito F, Dye JF, et al. Polydeoxyribonucleotide improves angiogenesis and wound healing in experimental thermal injury. Critical Care Medicine. 2008; 36: 1594–1602.

[9] Saramantos A, Kyrgidis A, Venetis G, Hatziantoniou G, Chrysostomidis A, Sardeli C, et al. Clinical efficacy of prolotherapy for temporomandibular joint disorders: a systematic review and meta-analysis. Clinics and Practice. 2025; 15: 51.

[10] Busse JW, Casassus R, Carrasco-Labra A, Durham J, Mock D, Zakrzewska JM, et al. Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline. The BMJ. 2023; 383: e076227.

[11] Ku JK, Choi JW, Kim YK. Degenerative temporomandibular joint disorder treated with prolotherapy: case series. Journal of Korean Dental Association. 2025; 63: 137–152.

[12] Zhou H, Xue Y, Liu P. Application of auriculotemporal nerve block and dextrose prolotherapy in exercise therapy of TMJ closed lock in adolescents and young adults. Head & Face Medicine. 2021; 17: 11.

[13] Bizzoca D, Brunetti G, Moretti L, Piazzolla A, Vicenti G, Moretti FL, et al. Polydeoxyribonucleotide in the treatment of tendon disorders, from basic science to clinical practice: a systematic review. International Journal of Molecular Sciences. 2023; 24: 4582.

[14] Refai H, Altahhan O, Elsharkawy R. The efficacy of dextrose prolotherapy for temporomandibular joint hypermobility: a preliminary prospective, randomized, double-blind, placebo-controlled clinical trial. Journal of Oral and Maxillofacial Surgery. 2011; 69: 2962–2970.

[15] Mustafa R, Güngörmüş M, Mollaoğlu N. Evaluation of the efficacy of different concentrations of dextrose prolotherapy in temporomandibular joint hypermobility treatment. Journal of Craniofacial Surgery. 2018; 29: e461–e465.

[16] Stefanovski V, Daskalova B, Mladenovski M, Gordan L, Sanja P. Visual analog scale for pain analysis in patients with temporomandibular dysfunction. Academic Medical Journal. 2022; 2: 128–134.

[17] Reeves KD, Hassanein KM. Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity. Alternative Therapies in Health and Medicine. 2003; 9: 58–62.

[18] Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Alternative Therapies in Health and Medicine. 2000; 6: 68–74, 77–80.

[19] Khan SA, Kumar A, Varshney MK, Trikha V, Yadav CS. Dextrose prolotherapy for recalcitrant coccygodynia. Journal of Orthopaedic Surgery. 2008; 16: 27–29.

[20] Park JS, Ku JK, Kim YK, Yun PY. Efficacy of dextrose prolotherapy on temporomandibular disorder: a retrospective study. Journal of the Korean Association of Oral and Maxillofacial Surgeons. 2024; 50: 259–264.

[21] Cialdai F, Risaliti C, Monici M. Role of fibroblasts in wound healing and tissue remodeling on earth and in space. Frontiers in Bioengineering and Biotechnology. 2022; 10: 958381.

[22] Assiri K, Alqarni A, Almubarak H, Mohammed Kaleem S, Alassiri S, Baig FAH, et al. Efficacy of prolotherapy for temporomandibular joint dysfunction: an interventional clinical study. Medical Science Monitor. 2025; 31: e946650.

[23] Waluyo Y, Artika SR, Insani Nanda Wahyuni, Gunawan AMAK, Zainal ATF. Efficacy of prolotherapy for osteoarthritis: a systematic review. Journal of Rehabilitation Medicine. 2023; 55: jrm00372.

[24] Fong HPY, Zhu MT, Rabago DP, Reeves KD, Chung VCH, Sit RWS. Effectiveness of hypertonic dextrose injection (prolotherapy) in plantar fasciopathy: a systematic review and meta-analysis of randomized controlled trials. Archives of Physical Medicine and Rehabilitation. 2023; 104: 1941–1953.e9.

[25] Filardo G, Kon E, Roffi A, Di Matteo B, Merli ML, Marcacci M. Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surgery, Sports Traumatology, Arthroscopy. 2015; 23: 2459–2474.

[26] Louw WF, Reeves KD, Lam SKH, Cheng AL, Rabago D. Treatment of temporomandibular dysfunction with hypertonic dextrose injection (prolotherapy): a randomized controlled trial with long-term partial crossover. Mayo Clinic Proceedings. 2019; 94: 820–832.

[27] Arena S, Minutoli L, Arena F, Nicotina PA, Romeo C, Squadrito F, et al. Polydeoxyribonucleotide administration improves the intra-testicular vascularization in rat experimental varicocele. Fertility and Sterility. 2012; 97: 165–168.

[28] Baek A, Kim Y, Lee JW, Lee SC, Cho SR. Effect of polydeoxyribonucleotide on angiogenesis and wound healing in an in vitro model of osteoarthritis. Cell Transplantation. 2018; 27: 1623–1633.

[29] Rabago D, Slattengren A, Zgierska A. Prolotherapy in primary care practice. Primary Care. 2010; 37: 65–80.

[30] Zhao AT, Caballero CJ, Nguyen LT, Vienne HC, Lee C, Kaye AD. A comprehensive update of prolotherapy in the management of osteoarthritis of the knee. Orthopedic Reviews. 2022; 14: 33921.

[31] Chęciński M, Chęcińska K, Turosz N, Brzozowska A, Chlubek D, Sikora M. Current clinical research directions on temporomandibular joint intra-articular injections: a mapping review. Journal of Clinical Medicine. 2023; 12: 4655.

[32] Zhang T, Wang Y, Ding L, Ma C. Efficacy of hypertonic dextrose proliferation therapy in the treatment of rotator cuff lesions: a meta-analysis. Journal of Orthopaedic Surgery and Research. 2024; 19: 297.